Prof. Dr. Beat Thürlimann

FMH für Medizinische Onkologie
FMH für Allgemeine Innere Medizin


Sprachen: Deutsch, English, Französisch, Italienisch

Kernkompetenz

  • Beratungen zu Risikofaktoren, Prognose, Diagnose, Untersuchungen, Therapie, Supportiv- und Komplementärmedizin, Nebenwirkungen von Brustkrebsbehandlungen

  • Zweitmeinungen zur Ersttherapie und zu nachfolgenden Therapien bei Brustkrebs und gynäkologischen Tumoren

  • Interdisziplinäre Behandlung

  • Genetische Beratung

  • Neue, innovative Therapien/Medikamente

  • Patientenbezogene Forschung

  • Internationale Forschungskoordination

Berufserfahrung

  • 2008 - 2020 Kantonsspital St. Gallen, Brustzentrum
    Chefarzt
  • 2001 – 2008 Kantonsspital St. Gallen, Senologiezentrum Ostschweiz
    Leitender Arzt
  • 1994 – 2000 Kantonsspital St. Gallen, Innere Medizin: Onkologie/Hämatologie
    Oberarzt mbF
  • 1990 – 1994 Kantonsspital St. Gallen, Innere Medizin: Onkologie/Hämatologie
    Oberarzt
  • 1988 – 1989 Kantonale Laboratorien St. Gallen, Institut für Klinische Chemie und Hämatologie
    Assistenzarzt
  • 1987 – 1988 Kantonsspital St. Gallen, Innere Medizin
    Assistenzarzt
  • 1985 – 1987 Kantonsspital St. Gallen, Onkologie/Hämatologie
    Assistenzarzt
  • 1983 – 1985 Hospital and University of Pretoria RSA, Department of Medical Oncology
    Senior Medical Officer
  • 1981 – 1983 Universitätsspital Zürich, Nuklearmedizin und Radiotherapie
    Assistenzarzt
  • 2021 Krebspreis der Krebsliga Schweiz für die «Patterns of care»-Studie, die Anlass zur Gründung des Qualitätslabels für Brustzentren «Q-Label» war

Ausbildung & Weiterbildung

  • 2005 Ernennung zum Titularprofessor, Universität Basel
  • 1998 Habilitation und Ernennung zum Privatdozenten der Universität Basel
  • 1991 Facharzt Medizinische Onkologie ESMO
  • 1991 Facharzt FMH Onkologie/Hämatologie
  • 1989 Facharzt FMH Innere Medizin
  • 1983 Dissertation, Universität Zürich
  • 1980 Medizinisches Staatsexamen
  • 1974 – 1980 Medizinstudium an der Universität Zürich

Lehrtätigkeit

• SAMO
• DESO seit 2010
• ESO-d European School of Oncology (1990 - 2009)
• Lehrtätigkeit: Universität Basel (seit 1998)
• Lehrauftrag: Kantonale Laborschule, St. Gallen (1988 – 1989)
• Lehrauftrag: Nuklearmedizin und Radio-Onkologie, Universitätsspital Zürich
(1981 – 1983)


Redaktionelle Mitarbeit bei Fachzeitschriften

• The Breast (Elsevier Publishers, Amsterdam) seit 2000, Editorial Board, Deputy Editor-in-Chief, Section Editor
• European Journal of Cancer (Elsevier Publishers, Oxford/Brüssel) 1995 – 2000, Editorial Board
• Onkologie (Karger-Verlag, Freiburg/Deutschland) 1993 – 1998, Editorial Board


Weitere berufliche Funktionen

• SAKK: Präsident 2010-2016
• SAKK: Past President seit 2016
• SAKK: Project Group Breast Cancer, Gynecology Working Group, Genetic Network, Network for Outcomes Research
• IBCSG Foundation Council: Präsident 2005-2008
• IBCSG Scientific Committee
• SSKK: Stiftungsrat
• SSKK: Stiftungsrat-Ausschuss seit 2017
• SONK: Stiftungsrat
• FEG (Fachexpertengremium Mammographie Screening Programm Kanton SG): Mitglied
• Rising Tide Foundation for Clinical Cancer Research: Stiftungsrat seit 2016, Vice-Chair
• KFS: Stiftungsrat seit 2017
• International Advisory Board Lithuanian National Cancer Institute seit 2018

Kongressorganisationen

• SGS (www.base.ch/senologie)
• Senologie Update (www.aerztenetzwerk.ch/web/SenologieUpdate.aspx)
• St. Gallen Oncology Conferences (www.oncoconferences.ch)
• St.Galler Senologie Symposium (www.kssg.ch/events)

Mitgliedschaften

• SAKK, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, (1993 – 2005 Präsident Brustkrebs-Projektgruppe)
• IBCSG, International Breast Cancer Study Group, (2005 – 2008 Präsident)
• ASCO, American Society of Clinical Oncology
• FMH, Verbindung Schweizer Ärztinnen und Ärzte
• SGMO, Schweizerische Gesellschaft für Medizinische Onkologie
• ESMO, European Society of Medical Oncology
• SGS,Schweizerische Gesellschaft für Senologie, Ehrenmitglied seit 2021

Publikationen

Burstein H J, Curigliano G, Thürlimann B, Weber W P, Poortmans P, Regan M M, Senn H J, Winer E P, Gnant M, Panelists Of The St Gallen Consensus Conference . Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32:1216-1235.

Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, Von Briel T, Anchisi S, Bohanes P, Blum V, Von Burg P, Mannhart M, Caspar C B, Von Moos R, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). BMC Cancer 2021; 21:182.

Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC Cancer 2021; 21:229.

Stoffel S T, Von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, Von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch J E, Mark M T. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal- related events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly 2021; 151:w20464.

Leone J P, Cole B F, Regan M M, Thürlimann B, Coates A S, Rabaglio M, Giobbie-Hurder A, Gelber R D, Ejlertsen B, Harvey V J, Neven P, Láng I, Bonnefoi H, Wardley A, Goldhirsch A, Di Leo A, Colleoni M, Vaz-Luis I, Lin N U. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. Cancer 2020;.

Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey V J, Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates A S, Gelber R D, Goldhirsch A, Colleoni M, Thürlimann B, Regan M M. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Res Treat 2020;.

Luen S J, Asher R, Lee C K, Savas P, Kammler R, Dell'orto P, Biasi O M, Demanse D, Hackl W, Thürlimann B, Viale G, Di Leo A, Colleoni M, Regan M M, Loi S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Ann Oncol 2020; 31:1359-1365.

Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D A, Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer 2020; 20:114.

Maranta A F, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast 2020; 51:120-126.

Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P, Thürlimann B, Members Of The St. Gallen International Consensus Panel On The Primary Therapy Of Early Breast Cancer 2019 . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.

Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann B, Senn H J. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. Ann Oncol 2019; 20:1751-1752.

Buechler S A, Gray K P, Gökmen-Polar Y, Willis S, Thürlimann B, Kammler R, Viale G, Leyland-Jones B, Badve S S, Regan M M. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.

Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel Members Of The St. Gallen International Expert Consensus On The Primary Therapy Of Early Breast Cancer 2017 . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2019; 30:1181.

Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, Von Briel T, Anchisi S, Bohanes P, Blum V, Von Burg P, Mannhart M, Caspar C B, Von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross- sectional study from Switzerland (SAKK 95/16). J Bone Oncol 2019; 21:100273.

Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel Members Of The St. Gallen International Expert Consensus On The Primary Therapy Of Early Breast Cancer 2017 . Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.

Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P, Thürlimann B, Members Of The St. Gallen International Consensus Panel On The Primary Therapy Of Early Breast Cancer 2019 . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.

Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, Von Moos R, Weder P, Zaman K, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC Cancer 2019; 19:902.

Denkert C, Budczies J, Regan M M, Loibl S, Dell'Orto P, Von Minckwitz G, Mastropasqua M G, Solbach C, Thürlimann B, Mehta K, Blohmer J U, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B M, Dietel M, Fasching P A, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat 2019; 176:557-568.

Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille J C, Hawle H, Klingbiel D, Thürlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.

Kensler K H, Regan M M, Heng Y J, Baker G M, Pyle M E, Schnitt S J, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi R M. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor- positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res 2019; 21:30.

Curigliano G, Burstein H J, Winer E P, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker S Y, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F, Huang C S, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J, Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T J, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2018; 29:2153.

Ess S M, Herrmann C, Bouchardy C, Neyroud I, Rapiti E, Konzelmann I, Bordoni A, Ortelli L, Rohrmann S, Frick H, Mousavi M, Thürlimann B. Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies. Breast 2018; 41:151-158.

Steger G, Lüftner D, Stöger H, Thürlimann B, Untch M. Management of HER2-Positive Early Breast Cancer. Breast Care (Basel) 2018; 13:453-455.

Dowsett M, Sestak I, Regan M M, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 2018; 36:1941-1948.

Wapnir I L, Price K N, Anderson S J, Robidoux A, Martín M, Nortier J W R, Paterson A H G, Rimawi M F, Láng I, Baena-Cañada J M, Thürlimann B, Mamounas E P, Geyer C E, Gelber S, Coates A S, Gelber R D, Rastogi P, Regan M M, Wolmark N, Aebi S, International Breast Cancer Study Group , NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group , Breast International Group . Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 2018; 36:1073-1079.

Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan M M, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist 2018;.

Baumann M, Dani S U, Dietrich D, Hochstrasser A, Klingbiel D, Mark M T, Riesen W F, Ruhstaller T, Templeton A J, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.

Luen S J, Asher R, Lee C K, Savas P, Kammler R, Dell'orto P, Biasi O M, Demanse D, JeBailey L, Dolan S, Hackl W, Thürlimann B, Viale G, Colleoni M, Regan M M, Loi S. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. JAMA Oncol 2018;.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M B, Ejlertsen B, De Azambuja E, Neven P, Láng I, Jakobsen E H, Gladieff L, Bonnefoi H, Harvey V J, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R D, Coates A S, Goldhirsch A, Thürlimann B, Regan M M, Members Of The BIG 1-98 Collaborative Group And The International Breast Cancer Study Group . Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol 2018;JCO1800440.

Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt C, Ess S. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open 2018; 8:e017806.

Zweifel M, Thürlimann B, Riniker S, Weder P, Von Moos R, Pagani O, Bigler M, Rothgiesser K M, Pilop C, Hawle H, Brauchli P, Tapia C, Schoenfeld W, Sessa C. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.

Bartlett J M S, Ahmed I, Regan M M, Sestak I, Mallon E A, Dell'orto P, Thürlimann B, Seynaeve C, Putter H, Van De Velde C J H, Brookes C L, Forbes J F, Viale G, Cuzick J, Dowsett M, Rea D W, . HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer 2017; 79:129-138.

Borgquist S, Giobbie-Hurder A, Ahern T P, Garber J E, Colleoni M, Láng I, Debled M, Ejlertsen B, Von Moos R, Smith I, Coates A S, Goldhirsch A, Rabaglio M, Price K N, Gelber R D, Regan M M, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol 2017; 35:1179-1188.

Curigliano G, Burstein H J, Winer E P, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker S Y, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F, Huang C S, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J, Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T J, Xu B. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol 2017.

Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F, Huang C S, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J, Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T J, Xu B. De- escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.

Klingbiel D, Thürlimann B, Brauchli P, Von Moos R. Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017;.

Warschkow R, Cerny T, Schmied B, Gueller U, Thürlimann B, Joerger M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R V, Zaman K, Goldhirsch A, . Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016;.

Colleoni M, Gray K P, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E A, Gomez H L, Linderholm B K, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R D, Regan M M, Coates A S, Price K N, Viale G, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016;.

Chirgwin J H, Giobbie-Hurder A, Coates A S, Price K N, Ejlertsen B, Debled M, Gelber R D, Goldhirsch A, Smith I, Rabaglio M, Forbes J F, Neven P, Láng I, Colleoni M, Thürlimann B. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 2016; 34:2452-9.

Crombag M R B S, Joerger M, Thürlimann B, Schellens J H M, Beijnen J H, Huitema A D R. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8:.

Warschkow R, Gueller U, Tarantino I, Cerny T, Schmied B, Thürlimann B, Joerger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.

Colleoni M, Sun Z, Price K N, Karlsson P, Forbes J F, Thürlimann B, Gianni L, Castiglione M, Gelber R D, Coates A S, Goldhirsch A. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016;.

Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary treatment, and adjuvant hormonal treatment. Breast Cancer 2015;.

Peters S, Von Moos R, Thürlimann B. [Is prescription of a therapy costing 150,000 CHF reasonable?]. Rev Med Suisse 2015; 11:1967-72.

Leyland-Jones B, Gray K P, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price K N, Coates A S, Goldhirsch A, Gelber R D, Pagani O, Viale G, Rae J M, Regan M M, BIG 1-98 Collaborative Group . ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat 2015; 154:543-55.

Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H J, Panel Members . -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26:1533-46.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes J F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R C, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, Van De Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386:1341-52.

Leyland-Jones B, Gray K P, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Lyng M B, Ditzel H J, Harvey V J, Neven P, Treilleux I, Rasmussen B B, Maibach R, Price K N, Coates A S, Goldhirsch A, Pagani O, Viale G, Rae J M, Regan M M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015; 151:373-84.

Hadji P, Coleman R E, Wilson C, Powles T J, Clézardin P, Aapro M, Costa L, Body J J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thürlimann B, Untch M, Cortes J, Martin M, Albert U S, Conte P F, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. Ann Oncol 2015;.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso M J, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, Macgrogan G, Michiels S, Negreiros I, Offersen B V, Penault Llorca F, Pruneri G, Roche H, Russell N S, Schmitt F, Servent V, Thürlimann B, Untch M, Van Der Hage J A, Van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli T S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015;.

Munzone E, Giobbie-Hurder A, Gusterson B A, Mallon E, Viale G, Thürlimann B, Ejlertsen B, Macgrogan G, Bibeau F, Lelkaitis G, Price K N, Gelber R D, Coates A S, Goldhirsch A, Colleoni M, International Breast Cancer Study Group And The BIG 1-98 Collaborative Group . Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol 2015;.

Senn H J, Thürlimann B, Gnant M. St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!. Breast 2015;.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso M J, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, Macgrogan G, Michiels S, Negreiros I, Offersen B V, Penault Llorca F, Pruneri G, Roche H, Russell N S, Schmitt F, Servent V, Thürlimann B, Untch M, Van Der Hage J A, Van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli T S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.

Herrmann C, Ess S, Thürlimann B, Probst-Hensch N, Vounatsou P. 40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland. BMC Cancer 2015; 15:666.

Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer E P, Thürlimann B, Gelber R D, Colleoni M, Ejlertsen B, Debled M, Price K N, Regan M M, Coates A S, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol 2015; 33:2772-9.

Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr H A, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS ONE 2015; 10:e0123435.

Templeton A, Ribi K, Surber C, Sun H, Hsu Schmitz S F, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, Von Rohr L, Winterhalder R C, Rochlitz C, Von Moos R, Zaman K, Thürlimann B, Ruhstaller T, Swiss Group For Clinical Cancer Research (SAKK) Coordinating Center . Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244-9.

Knauer M, Thürlimann B. Adjuvant bisphosphonates in breast cancer treatment. Breast Care (Basel) 2014; 9:319-22.

Huober J, Thürlimann B. Bone targeted therapy in breast cancer - an old concept but still much to do. Breast Care (Basel) 2014; 9:310.

Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price K N, Gelber R D, Goldhirsch A, Coates A S, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.

Aebi S, Gelber S, Anderson S J, Láng I, Robidoux A, Martín M, Nortier J W R, Paterson A H G, Rimawi M F, Cañada J M B, Thürlimann B, Murray E, Mamounas E P, Geyer C E, Price K N, Coates A S, Gelber R D, Rastogi P, Wolmark N, Wapnir I L, CALOR Investigators .
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 2014; 15:156-63.

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.

Oakman C, Francis P A, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R D, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol 2013; 24:1203-11.

Huober J, Cole B F, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes J F, Neven P, Láng I, Smith I, Wardley A, Price K N, Goldhirsch A, Coates A S, Colleoni M, Gelber R D, Thürlimann B, BIG 1-98 Collaborative And International Breast Cancer Study Groups . Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.

Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.

Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.

Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M, Thürlimann B, Senn H J, Panel Members . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.

Templeton A J, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller
T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer 2013; 13:153.

Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.

Karlsson P, Cole B F, Chua B H, Price K N, Lindtner J, Collins J P, Kovács A, Thürlimann B, Crivellari D, Castiglione-Gertsch M, Forbes J F, Gelber R D, Goldhirsch A, Gruber G, International Breast Cancer Study Group . Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23:2852-8.

Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clin Breast Cancer 2012; 12:102-9.

Huober J, Gelber S, Goldhirsch A, Coates A S, Viale G, Oehlschlegel C, Price K N, Gelber R D, Regan M M, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843-51.

Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.

Ribi K, Aldridge J, Phillips K A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D, Bernhard J, BIG 1-98 Collaborative Group , International Breast Cancer Study Group . Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.

Regan M M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Lyng M B, Ditzel H J, Neven P, Debled M, Maibach R, Price K N, Gelber R D, Coates A S, Goldhirsch A, Rae J M, Viale G, Breast International Group (BIG) 1-98 Collaborative Group . CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.

Ewertz M, Gray K P, Regan M M, Ejlertsen B, Price K N, Thürlimann B, Bonnefoi H, Forbes J F, Paridaens R J, Rabaglio M, Gelber R D, Colleoni M, Láng I, Smith I E, Coates A S, Goldhirsch A, Mouridsen H T. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.

Huober J, Baumann M, Rochlitz C, Aebi S, Güth U, Von Moos R, Müller A, Von Rohr L, Widmer I, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology 2011; 81:160-166.

Chirgwin J, Sun Z, Smith I, Price K N, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan M M, Goldhirsch A, Coates A S, BIG 1-98 Collaborative And International Breast Cancer Study Groups . The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.

Mark M, Thürlimann B. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med Oncol 2011.

Regan M M, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes J F, Smith I, Láng I, Wardley A, Rabaglio M, Price K N, Gelber R D, Coates A S, Thürlimann B, BIG 1-98 Collaborative Group , International Breast Cancer Study Group (IBCSG) .
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12:1101-8.

Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clin Breast Cancer 2011;.

Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie- Hurder A, Berthod G, Genton C, Brauchli P, Aebi S, On Behalf Of The Swiss Group For Clinical Cancer Research (SAKK) . Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG
1-98 study (SAKK 21/07). Ann Oncol 2011;.

Viale G, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, For The BIG 1-98 Collaborative And International Breast Cancer Study Groups . Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.

Regan M M, Price K N, Giobbie-Hurder A, Thürlimann B, Gelber R D, For The International Breast Cancer Study Group And BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011; 13:209.

Bolla D, Bolla, Geb. Wiedemann N, Oehlschlegel C, Schoening A, Stickel J, Thürlimann B, Hornung R. Pseudoangiomatous stromal hyperplasia of breast in man: a case report. Breast J 2011; 17:311-2.

Goldhirsch A, Wood W C, Coates A S, Gelber R D, Thürlimann B, Senn H J, Panel Members .
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47.

Colleoni M, Giobbie-Hurder A, Regan M M, Thürlimann B, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price K N, Gelber R D, Coates A S, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.

Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, Von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thürlimann B, Swiss Group For Clinical Cancer Research (SAKK) . Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.

Joerger M, Templeton A, Koeberle D, Engler H, Riesen W F, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010;.

Mouridsen H T, Lønning P, Beckmann M W, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther 2010; 10:1825-1836.

Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136.

Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.

Thürlimann B. [Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark-a comparative Study"]. Praxis (Bern 1994) 2010; 99:1217-8.

Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monographs 2010; 2010:162-77.

Joerger M, Riesen W F, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010;.

Phillips K A, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2010.

Baumann M, Thürlimann B, Ruhstaller T. Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation. Breast Care 2010; 5:188-191.

Phillips K A, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010; 19:388-95.

The Scientific Board , Harbeck N, Von Minckwitz G, Thürlimann B. Bisphosphonates in adjuvant treatment of early breast cancer. Crit Rev Oncol Hematol 2010; 74S1:S1.

Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol 2010; 34:116-21.

Huober J, Thürlimann B. Bone targeted therapy in breast cancer: present and future. Crit Rev Oncol Hematol 2010; 74S1:S7-S10.

Brauchli P, Thürlimann B, Crowe S N, Herrmann R. What is the value of the 21-gene recurrence score?. J Clin Oncol 2010; 28:e671-2.

Paridaens R J, Gelber S, Cole B F, Gelber R D, Thürlimann B, Price K N, Holmberg S B, Crivellari D, Coates A S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2010; 123:303-10.

Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thürlimann B, Giobbie- Hurder A, Viale G, Altermatt H J, Aebi S, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer 2010; 10:37.

Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 2010; 56:69-70.

Von Moos R, Caspar C B, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B. Long- term renal safety profile of ibandronate 6 mg infused over 15 minutes. Onkologie 2010; 33:447-50.

Ess S, Savidan A, Bouchardy C, Bordoni A, Konzelmann I, Jundt G, Probst N, Frick H, Thürlimann B. Patterns of care of breast cancer patients in Switzerland: A population based study : Advisory Board: Bachmann G, St.Gallen (Public Health), Lütolf U, Zurich (Radio Oncology), Obrist R, Sion (Medical Oncology), Rageth Ch, Zurich (Breast Surgery), Vlastos G, Geneva (Breast Surgery), Thürlimann B, St.Gallen (Medical Oncology). http://www.krebsliga-sg.ch/d/krebsregister/index.cfm 2009;.

Huober J, Thürlimann B. The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer. Breast Care (Basel) 2009; 4:367-372.

Huober J, Thürlimann B. Polychemotherapy in metastatic breast cancer - pro. Breast Care 2009; 4:367-372.

Giobbie-Hurder A, Price K N, Gelber R D, International Breast Cancer Study Group , BIG 1-98 Collaborative Group . Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 2009; 6:272-87.

Thürlimann B. Some comments to the Pattern of Care Study. Schweiz. Krebsbulletin 2009; 3:212-212.

Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's new in breast cancer therapy?. Breast Care 2009; 4:268-271.

Jakesz R, Dubsky P, Eidtman H, Schem C, Lang A, Thürlimann B. Neue Erkenntnisse vom SABCS, Expert Discussion. Breast Care 2009; 4:55-60.

Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.

Colleoni M, Sun Z, Martinelli G, Basser R L, Coates A S, Gelber R D, Green M D, Peccatori F, Cinieri S, Aebi S, Viale G, Price K N, Goldhirsch A, International Breast Cancer Study Group . The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 2009; 20:1344-51.

Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009; 4:268-271.

Huober J, Thürlimann B. Adjuvant! When the new world meets the old world. The Lancet 2009; 10:1028-9.

Thürlimann B, Price K N, Gelber R D, Holmberg S B, Crivellari D, Colleoni M, Collins J, Forbes J F, Castiglione-Gertsch M, Coates A S, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113:137-44.

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price K N, Gelber R D, Holmberg S B, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey M F, Murray E, Forbes J F, Coates A S, Goldhirsch A, International Breast Cancer Study Group . Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine- responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009; 116:491-500.

Rabaglio M, Sun Z, Price K N, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes J F, Paridaens R J, Colleoni M, Pienkowski T, Nogaret J M, Láng I, Smith I, Gelber R D, Goldhirsch A, Coates A S, BIG 1-98 Collaborative And International Breast Cancer Study Groups . Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.

Pagani O, Price K N, Gelber R D, Castiglione-Gertsch M, Holmberg S B, Lindtner J, Thürlimann B, Collins J, Fey M F, Coates A S, Goldhirsch A, International Breast Cancer Study Group (IBCSG) . Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117:319-24.

Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann B, Senn H J, Panel Members . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319-29.

Templeton A, Thürlimann B, Joerger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009;114-117.

Ruhstaller T, Von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thürlimann B. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 2009; 76:142-8.

BIG 1-98 Collaborative Group , Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J F, Price K N, Regan M M, Gelber R D, Coates A S. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. NEJM 2009; 361:766-76.

Joerger M, Senn H J, Thürlimann B. St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. magazine of european medical oncology 2009; 2:229-231.

Bernhard J, Zahrieh D, Zhang J J, Martinelli G, Basser R, Hürny C, Forbes J F, Aebi S, Yeo W, Thürlimann B, Green M D, Colleoni M, Gelber R D, Castiglione-Gertsch M, Price K N, Goldhirsch A, Coates A S, International Breast Cancer Study Group . Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.

Coates A, Mouridsen H, Thürlimann B, BIG 1-98 Collaborative Group. Inappropriate ATAC on tamoxifen. The Lancet 2008; 9:315-6.

Von Moos R, Thürlimann B, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture M E, Lademann J, Hauschild A. Pegylated liposomal doxorubicin- associated hand-foot syndrome: recommendations of an international panel of experts. EJO 2008; 44:781-90.

Von Moos R, Caspar C B, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann Oncol 2008; 19:1266-70.

Crivellari D, Sun Z, Coates A S, Price K N, Thürlimann B, Mouridsen H, Mauriac L, Forbes J F, Paridaens R J, Castiglione-Gertsch M, Gelber R D, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith I E, Chirgwin J H, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. JCO 2008; 26:1972-9.

Regan M M, Pagani O, Walley B, Torrisi R, Perez E A, Francis P, Fleming G F, Price K N, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates A S, Goldhirsch A, Gelber R D, SOFT/TEXT/PERCHE Steering Committee , International Breast Cancer Study Group . Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008; 19:1231-41.

Aapro M, Abrahamsson P A, Body J J, Coleman R E, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi G N, Jonat W, Lipton A, Monnier A, Paterson A H G, Rizzoli R, Saad F, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-32.

Rasmussen B B, Regan M M, Lykkesfeldt A E, Dell'Orto P, Del Curto B, Henriksen K L, Mastropasqua M G, Price K N, Méry E, Lacroix-Triki M, Braye S, Altermatt H J, Gelber R D, Castiglione-Gertsch M, Goldhirsch A, Gusterson B A, Thürlimann B, Coates A S, Viale G, BIG 1-98 Collaborative And International Breast Cancer Study Groups . Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.

Huober J, Thürlimann B. [Adjuvant endocrine therapy in breast cancer]. Therapeutische Umschau. Revue thérapeutique 2008; 65:193-200.

Spirig C, Thürlimann B, Huober J. [New treatment approaches in breast cancer]. Therapeutische Umschau. Revue thérapeutique 2008; 65:207-10.

Strasser F, Demmer-Steingruber R, Boehme C, Schmitz S F H, Thürlimann B, Cerny T, Gillessen S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. The Oncologist 2008; 13:337-46.

Pestalozzi B C, Zahrieh D, Mallon E, Gusterson B A, Price K N, Gelber R D, Holmberg S B, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates A S, Goldhirsch A, International Breast Cancer Study Group . Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. JCO 2008; 26:3006-14.

Viale G, Giobbie-Hurder A, Regan M M, Coates A S, Mastropasqua M G, Dell'Orto P, Maiorano E, MacGrogan G, Braye S G, Oehlschlegel C, Neven P, Orosz Z, Olszewski W P, Knox F, Thürlimann B, Price K N, Castiglione-Gertsch M, Gelber R D, Gusterson B A, Goldhirsch A, Breast International Group Trial 1-98 . Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.

Strasser F, Lutz T A, Maeder M T, Thürlimann B, Bueche D, Tschöp M, Kaufmann K, Holst B, Brändle M, Von Moss R, Cerny T, Demmer-Steingruber R. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. BJC 2008; 98:300-8.

Greuter S, Schmid F, Ruhstaller T, Thürlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008; 19:2091-2.

Gruber G, Cole B F, Castiglione-Gertsch M, Holmberg S B, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey M F, Gelber R D, Coates A S, Price K N, Goldhirsch A, Viale G, Gusterson B A, International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008; 19:1393-401.

Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret J M, Gelber R D, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group , International Breast Cancer Study Group . Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.

Brustzentren in der Schweiz. Schweizer Zeitschrift für Onkologie 2007; 4:22-23. Kapp U, Fürstenberger G. Die Primärbehandlung des frühen Mammakarzinoms : Internationale St. Gallen-Konsensus Konferenz 2007. Schweizer Zeitschrift für Onkologie 2007; 4:6-10.

International Breast Cancer Study Group, Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber R D, Price K N, Castiglione-Gertsch M, Coates A S, Goldhirsch A. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol 2007; 18:1177-84.

Koeberle D, Thürlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 2007; 105 Suppl 1:55-66.

Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Koeberle D, Goldhirsch A, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-9.

Thürlimann B, Koeberle D, Senn H J. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. EJC 2007; 43:46-52.

Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber R D, Forbes J F, Murray E, Collins J, Aebi S, Thürlimann B, Price K N, Goldhirsch A, Coates A S, International Breast Cancer Study Group Trial VIII . Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. JCO 2007; 25:263-70.

Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thürlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007; 18:1329-34.

Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price K N, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber R D, Coates A S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.

Ribi K, Bernhard J, Rufibach K, Thürlimann B, Von Moos R, Ruhstaller T, Glaus A, Böhme C. Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. JSCC 2007; 15:1349-56.

Karlsson P, Cole B F, Price K N, Coates A S, Castiglione-Gertsch M, Gusterson B A, Murray E, Lindtner J, Collins J P, Holmberg S B, Fey M F, Thürlimann B, Crivellari D, Forbes J F, Gelber R D, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.

Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann B, Senn H J, 10th St. Gallen Conference . Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-44.

Viale G, Regan M M, Maiorano E, Mastropasqua M G, Dell'Orto P, Rasmussen B B, Raffoul J, Neven P, Orosz Z, Braye S, Oehlschlegel C, Thürlimann B, Gelber R D, Castiglione- Gertsch M, Price K N, Goldhirsch A, Gusterson B A, Coates A S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.

Mouridsen H, Keshaviah A, Coates A S, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes J F, Paridaens R, Gelber R D, Colleoni M, Smith I, Price K N, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007; 25:5715-22.

Coates A S, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J M, Pienkowski T, Wardley A, Jakobsen E H, Price K N, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007; 25:486-92.

Thürlimann B. Reducing the risk of early recurrence in hormone-responsive breast cancer. Ann Oncol 2007; 18 Suppl 8:viii8-17.

Hess D, Koeberle D, Thürlimann B, Pagani O, Schonenberger A, Mattmann S, Rochlitz C, Rauch D, Schuller J C, Ballabeni P, Ribi K, Swiss Group For Clinical Cancer Research . Capecitabine and vinorelbine as first-line treatment in elderly patients ( or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.

Ruhstaller T, Thürlimann B, Koeberle D, Von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. JCO 2007; 25:4025-6; author reply 4026-7.

Salzberg M, Thürlimann B, Hasler U, Delmore G, Von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, Von Moos R. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 2007; 72:147-51.

Seeholzer N, Thürlimann B, Koeberle D, Hess D, Korte W. Combining chemotherapy and low- molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23.

Maschke U, Kränzlin M, Krapf R, Pecherstorfer M, Strebel U, Thürlimann B. Übersicht Bisphosphonate. Pharmakritik 2006; 28:17-20.

Thürlimann B. Aromatasehemmer in der modernen Brustkrebstheraphie. Bulletin Leben wie zuvor 2006; 66:19-22.

Langenegger T, Wahl P, Schiesser D, Thürlimann B. Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. Breast Cancer Res Treat 2006; 100:177-81.

Koeberle D, Thürlimann B. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. Expert review of anticancer therapy 2006; 6:5-10.

Ruhstaller T, Roe H, Thürlimann B, Nicoll J J. The multidisciplinary meeting: An indispensable aid to communication between different specialities. EJC 2006; 42:2459-62.

Glaus A, Boehme C, Thürlimann B, Ruhstaller T, Hsu Schmitz S F, Morant R, Senn H J, Von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17:801-6.

Goldhirsch A, Coates A S, Gelber R D, Glick J H, Thürlimann B, Senn H J, St Gallen Expert Panel Members . First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17:1772-6.

Fürstenberger G, Von Moos R, Lucas R, Thürlimann B, Senn H J, Hamacher J, Boneberg E M. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. BJC 2006; 94:524-31.

Pagani O, Sessa C, Nolè F, Munzone E, Crivellari D, Lombardi D, Thürlimann B, Hess D, Graffeo R, Ruggeri M, Longhi S, Goldhirsch A. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 2005; 16:1609-17.

Colleoni M, Zahrieh D, Gelber R D, Holmberg S B, Mattsson J E, Rudenstam C M, Lindtner J, Erzen D, Snyder R, Collins J, Fey M F, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates A S, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. JCO 2005; 23:1390-400.

Thürlimann B, Senn H J. [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)]. Gynäkologisch- geburtshilfliche Rundschau 2005; 45:143-6.

Colleoni M, Li S, Gelber R D, Coates A S, Castiglione-Gertsch M, Price K N, Lindtner J, Rudenstam C M, Crivellari D, Collins J, Pagani O, Simoncini E, Thürlimann B, Murray E, Forbes J, Erzen D, Holmberg S, Veronesi A, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16:716-25.

Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thürlimann B, Senn H J, Panel Members . Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16:1569-83.

Koeberle D, Thürlimann B. Adjuvant endocrine therapy in postmenopausal breast cancer patients. Breast (Edinburgh, Scotland) 2005; 14:446-51.

Gruber G, Bonetti M, Nasi M L, Price K N, Castiglione-Gertsch M, Rudenstam C M, Holmberg S B, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey M F, Gelber R D, Coates A S, Goldhirsch A, International Breast Cancer Study Group. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. JCO 2005; 23:7089-97.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates A S, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Rabaglio M, Smith I, Wardley A, Wardly A, Price K N, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM 2005; 353:2747-57.

Salzberg M, Thürlimann B, Bonnefois H, Fink D, Rochlitz C, Von Moos R, Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68:293-8.

Berclaz G, Li S, Price K N, Coates A S, Castiglione-Gertsch M, Rudenstam C M, Holmberg S B, Lindtner J, Erien D, Collins J, Snyder R, Thürlimann B, Fey M F, Mendiola C, Werner I D, Simoncini E, Crivellari D, Gelber R D, Goldhirsch A, International Breast Cancer Study Group . Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15:875-84.

Allal A S, Ares C, Dulguerov P, Tschanz E, Verdan C, Mhawech P, Riesterer O, Honer M, Vuong V, Jochum W, Zingg D, Bodis S, Ametamey S, Pruschy M, Inteeworn N, Ohlerth S, Höpfl G, Roos M, Wergin M, Rohrer Bley C, Gassmann M, Kaser-Hotz B, Berthou S, Aebersold D M, Ganapathipillai S, Streit B, Stalder D, Gruber G, Greiner R H, Zimmer Y, Lutters G, Krek W, Tenzer A, Hofstetter B, Bonny C, Azria A, Larbouret C, Cunat S, Ozsahin M, Zouhair A, Gourgou S, Martineau P, Evans D B, Romieu G, Pujol P, Pèlegrin A, Heuberger J, Kestenholz P, Taverna C, Lardinois D, Jörger M, Schneiter D, Jerman M, Weder W, Stahel R, Bodis S, Vees H, Mach N, Hügli A, Balmer Majno S, Beer K T, Friedrich E E, Ciernik I F, Stanek N, Taverna C, Greiner R, Mahler F, Landmann C, Studer G, Bernier J, Gallino A, Juelke P D, Hafner H P, Jamshidi P, Erne P, Resink T J, Thum P, Notter M, Bargetzi M, Suleiman M, Luthi J C, Bieri S, Curschmann J, Pajic B, Kranzbühler H, Lippold B, Ueltschi G, Bonetti M, Nasi M L, Price K N, Castiglione-Gertsch M, Rudenstam C M, Holmberg S B, Lindtner J, Gol-Ouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey M F, Gelber R D, Coates A S, Goldhirsch A, Jeanneret Sozzi W, Kramar A, Mirimanoff R O, Azria D, Taussky D, Becker M, Kranzbuehler H, Weitzel M, Bortoluzzi L, Behrensmeier F, Isaak B, Pasche P, Luthi F, Weber D C, Lomax A J, Rutz H P, Pedroni E S, Verwey J, Goitein G, Timmermann B, Lomax A, Bolsi A, Weber D, Bentzen S M, Khalil A A, Saunders M I, Horiot J C, Van Den Bogaert W, Cummings B J, Dische S, Slosman D O, Kebdani T, Allaoua M, Stadelmann O, Stupp R, Pica A, Dubois J B, Oehler C, Ulmer U, Lütolf U M, Huser M, Burger C, Szekely G, Davis J B, Gervaz P, Gertsch P, Morel P, Roth A D, Zenklusen H, Schott A, Curti G, Schefer H, Kolotas C, Thalmann G, Vetterli D, Kemmerling L, Mini R, Rouzaud M, Nouet P, Mollà M, Escudé L, Miralbell R, Beer K, Von Briel C, Jichlinski P, Guillou L, Fogliata A, Nicolini G, Cozzi L, Hafner H P, Hueber P, Szczerba D, Born E J, Dipasquale G, Jargy C, Munier F, Balmer A, Do H P, Pasche G, Wang H, Moeckli R, Boehringer T, Coray A, Lin S, Pedroni E, Rutz H, Baumert B G, Norton I A, Schoenmaker E, Krayenbühl J, Bründler M A, Allemann K, Laluhovà D, Collen T, Coucke P, Ries G, Rufibach K, Huguenin P, Abdou M, Girardet C, Vees H J, Bigler R, Özsoy O, Bouville S, Corminboeuf F, Betz M, Matzinger O, Tebeu P, Popowski Y, Verkooijen H, Bouchardy C, Ludicke F, Usel M, Major A, Merçay A, Pache G, Bulling S, Bressan S, Valley J F, Motta M, Presilla S, Richetti A, Franzetti A, Pesce G. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). Strahlenther Onkol 2004; 180 Suppl 1:89-108.

Koeberle D, Perey L, Thürlimann B, Swiss Group For Clinical Cancer Research (SAKK) . Re: Playing the old piano: another tune for endocrine therapy. Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7.

Thürlimann B, Müller A, Senn H J. Management of primary breast cancer: an update. Onkologie 2004; 27:175-9.

Thürlimann B, Hess D, Koeberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross- over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85:247-54.

Hess D, Thürlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, Rufener B, Castiglione- Gertsch M, Goldhirsch A, Swiss Group Of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology:official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.

Sabbioni M E E, Bernhard J, Siegrist H P, Schmitz S F H, Gertsch M C, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C, Swiss Group For Clinical Cancer Research (SAKK) . Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.

Bernhard J, Zahrieh D, Coates A S, Gelber R D, Castiglione-Gertsch M, Murray E, Forbes J F, Perey L, Collins J, Snyder R, Rudenstam C M, Crivellari D, Veronesi A, Thürlimann B, Fey M F, Price K N, Goldhirsch A, Hürny C. Quantifying trade-offs: quality of life and quality- adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. BJC 2004; 91:1893-901.

Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann B, Senn H J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:3357-65.

Von Moos R, Thürlimann B. Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study. Onkologie 2003; 26:128-32.

Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K W, Borner M M, Swiss Group For Clinical Cancer Research (SAKK) . Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21.

Aapro M S, Thürlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group For Clinical Cancer Research . A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7.

Thürlimann B, Robertson J F R, Nabholtz J M, Buzdar A, Bonneterre J, Arimidex Study Group .
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7.

Nabholtz J M, Bonneterre J, Buzdar A, Robertson J F R, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9.

Senn H J, Thürlimann B. The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'. Breast (Edinburgh, Scotland) 2003; 12:349-50.

Senn H J, Thürlimann B, Goldhirsch A, Wood W C, Gelber R D, Coates A S. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast (Edinburgh, Scotland) 2003; 12:569-82.

Wallgren A, Bonetti M, Gelber R D, Goldhirsch A, Castiglione-Gertsch M, Holmberg S B, Lindtner J, Thürlimann B, Fey M, Werner I D, Forbes J F, Price K, Coates A S, Collins J, International Breast Cancer Study Group Trials I Through VII . Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13.

Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro M S, Swiss Group For Clinical Cancer Research . Patients' estimation of overall treatment burden: why not ask the obvious?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72.

Thürlimann B. Anastrozole versus progestins/tamoxifen. Eur J Cancer 2002; 38 Suppl 6: S49-51.

Morant R, Hsu Schmitz S F, Bernhard J, Thürlimann B, Borner M, Wernli M, Egli F, Forrer P, Streit A, Jacky E, Hanselmann S, Bauer J, Hering F, Schmid H P. Vinorelbine in androgen- independent metastatic prostatic carcinoma--a phase II study. European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32.

Colleoni M, Litman H J, Castiglione-Gertsch M, Sauerbrei W, Gelber R D, Bonetti M, Coates A S, Schumacher M, Bastert G, Rudenstam C M, Schmoor C, Lindtner J, Collins J, Thürlimann B, Holmberg S B, Crivellari D, Beyerle C, Neumann R L A, Goldhirsch A, International Breast Cancer Study Group , German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British journal of cancer 2002; 86:1705-14.

Colleoni M, Gelber S, Coates A S, Castiglione-Gertsch M, Gelber R D, Price K, Rudenstam C M, Lindtner J, Collins J, Thürlimann B, Holmberg S B, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A, International Breast Cancer Study Group . Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9.

Koeberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. Expert review of anticancer therapy 2001; 1:169-76.

Thürlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast cancer (Tokyo, Japan) 2001; 8:294-7.

Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A, International Breast Cancer Study Group . High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6.

Bonneterre J, Buzdar A, Nabholtz J M, Robertson J F, Thürlimann B, Von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee , Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.

Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber R D, Rudenstam C M, Thürlimann B, Price K N, Coates A S, Hürny C, Bernhard J, Lindtner J, Collins J, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22.

Gessner U, Koeberle D, Thürlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22.

Colleoni M, Bonetti M, Coates A S, Castiglione-Gertsch M, Gelber R D, Price K, Rudenstam C M, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:584-90.

Vergote I, Bonneterre J, Thürlimann B, Robertson J, Krzakowski M, Mauriac L, Koralewski L, Webster A, Steinberg M, Von Euler M. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5.

Thürlimann B. Small-cell lung cancer with brain metastases and survival for more than 15 years despite incomplete therapy. Onkologie 2000; 23:64-66.

Morant R, Bernhard J, Maibach R, Borner M, Fey M F, Thürlimann B, Jacky E, Trinkler F, Bauer J, Zulian G, Hanselmann S, Hürny C, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 2000; 11:183-8.

Bonneterre J, Thürlimann B, Robertson J F, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, Von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57.

Pagani O, Sessa C, Nolè F, Crivellari D, Lombardi D, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91.

Aebi S, Gelber S, Castiglione-Gertsch M, Gelber R D, Collins J, Thürlimann B, Rudenstam C M, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner I D, Coates A S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor- positive breast cancer?. Lancet 2000;355:1869-74.

Sabbioni M E, Siegrist H P, Bacchi M, Bernhard J, Castiglione M, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast cancer research and treatment 2000; 59:279-87.

Colleoni M, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann B, Price K N, Castiglione-Gertsch M, Coates A S, Lindtner J, Collins J, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam C M. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.

Sabbioni M E, Castiglione M, Hürny C, Siegrist H P, Bacchi M, Bernhard J, Thürlimann B, Bonnefoi H, Perey L, Goldhirsch A, Senn H J. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53.

Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thürlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 1999; 10:539-45.

Koeberle D, Bacchus L, Thürlimann B, Senn H J. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7.

Bernhard J, Castiglione-Gertsch M, Schmitz S F, Thürlimann B, Cavalli F, Morant R, Fey M F, Bonnefoi H, Goldhirsch A, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1999; 35:913-20.

Rizzoli R, Thiébaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss H J, Rückert F, Manegold C, Tubiana-Hulin M, Steinhauer E U, Degardin M, Thürlimann B, Clemens M R, Eghbali H, Body J J. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. The Journal of clinical endocrinology and metabolism 1999; 84:3545-50.

Bernhard J, Thürlimann B, Schmitz S F, Castiglione-Gertsch M, Cavalli F, Morant R, Fey M F, Bonnefoi H, Goldhirsch A, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9.

Lehnert M, Mross K, Schueller J, Thürlimann B, Kroeger N, Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. British journal of cancer 1998; 77:1155-63.

Engler H, Koeberle D, Thürlimann B, Senn H J, Riesen W F. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85.

Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A. Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. British journal of cancer 1998; 77:985-91.

Pagani O, O'Neill A, Castiglione M, Gelber R D, Goldhirsch A, Rudenstam C M, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn H J. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. European journal of cancer (Oxford, England : 1990) 1998; 34:632-40.

Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber R D, Thürlimann B, Rudenstam C M. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700.

Bernhard J, Hürny C, Coates A S, Peterson H F, Castiglione-Gertsch M, Gelber R D, Galligioni E, Marini G, Thürlimann B, Forbes J F, Goldhirsch A, Senn H J, Rudenstam C M. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). British journal of cancer 1998; 78:686-93.

Lønning P E, Paridaens R, Thürlimann B, Piscitelli G, Di Salle E. Exemestane experience in breast cancer treatment. The Journal of steroid biochemistry and molecular biology 1997; 61:151-5.

Thürlimann B, Castiglione M, Hsu-Schmitz S F, Cavalli F, Bonnefoi H, Fey M F, Morant R, Löhnert T, Goldhirsch A. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1997;33:1017-24.

Ralston S H, Thiébaud D, Herrmann Z, Steinhauer E U, Thürlimann B, Walls J, Lichinitser M R, Rizzoll R, Hagberg H, Huss H J, Tubiana-Hulin M, Body J J. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. British journal of cancer 1997; 75:295-300.

Goldhirsch A, Gelber R D, Castiglione M, O'Neill A, Thürlimann B, Rudenstam C M, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey M F, Pagani O, Price K, Senn H J. Menstrual cycle and timing of breast surgery in premenopausal node- positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997; 8:751-6.

Nabholtz J M, Thürlimann B, Bezwoda W R, Melnychuk D, Deschênes L, Douma J, Vandenberg T A, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Aapro M S, Alaki M, Murawsky M, Riva A. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park, N.Y.) 1997; 11:25-30.

Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, Di Salle E, Lanzalone S, Zurlo M G, Piscitelli G. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73.

Senn, Lampert, Thürlimann B. Therapy of Primary Breast Cancer in the 21st Century: A Prediction. Breast cancer (Tokyo, Japan) 1997; 4:213-220.

Erlichman C, Fine S, Kerr I, Hoffmann W, Gorg C, Schmoll H J, Preusser P, Thürlimann B, Gustavsson B. A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. American journal of clinical oncology 1996; 19:26-31.

Thürlimann B, De Stoutz N D. Causes and treatment of bone pain of malignant origin. Drugs 1996; 51:383-98.

Pecherstorfer M, Herrmann Z, Body J J, Manegold C, Degardin M, Clemens M R, Thürlimann B, Tubiana-Hulin M, Steinhauer E U, Van Eijkeren M, Huss H J, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996; 14:268-76.

Thürlimann B, Senn H J. The changing approach to the treatment of early breast cancer. The New England journal of medicine 1996; 334:1397-9.

Hagen M F, Thürlimann B. [Hormone therapy of metastasizing breast carcinoma]. Therapeutische Umschau. Revue thérapeutique 1996; 53:820-8.

Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi W F, Cavalli F, Senn H J, Fey M, Löhnert T. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9.

Joss R A, Alberto P, Hürny C, Bacchi M, Leyvraz S, Thürlimann B, Cerny T, Martinelli G, Stahel R, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.

Thürlimann B, Kröger N, Greiner J, Mross K, Schüller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Journal of cancer research and clinical oncology 1995; 121 Suppl 3:R3-6.

Thürlimann B. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?. Ann Oncol 1994; 5 Suppl 7:S45-7.

Thürlimann B. Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis. Arch Gynecol Obstet 1994; 255 Suppl 2:S379-80.

Joss R A, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro M S, Thürlimann B. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5:253-8.

Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi W F, Thürlimann B, Cavalli F, Obrecht J P. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071-7.

Thürlimann B, Morant R, Jungi W F, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2:61-5.

Thürlimann B, Waldburger R, Senn H J, Thiébaud D. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol 1992; 3:619-23.

Thürlimann B, Bachmann I. Effective prevention of chemotherapy--induced phlebitis by low- dose heparin: a prospective randomised trial. Ann Oncol 1992; 3:311-3.

Morant R, Thürlimann B, Jungi W F, Schmid L, Holdener E, Schmid U, Senn H J. [Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]. Schweiz Med Wochenschr 1991; 121:344-6.

Schmid L, Thürlimann B, Müller M, Senn H J. Recombinant human granulocyte-macrophage colony-stimulating factor for the intensification of cytostatic treatment in advanced cancer. Recent Results Cancer Res 1991; 121:173-81.

Schmid L, Jeschko M, Wilder-Smith C, Schafroth U, Thürlimann B, Pedrazzini A, Senn H. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia. Chemotherapy 1991; 37:346-52.

Thürlimann B, Senn H J, Jungi W F. Anthracycline-carboplatin combination in metastatic breast cancer. J Cancer Res Clin Oncol 1990; 116:13-4.

Thürlimann B, Senn H J. [Safety problems in the handling of cytostatics]. Ther Umsch 1988; 45:403-7.

Coccia-Portugal M A, Sieling W L, Terblanche A P, Thürlimann B, Van Rensburg P G, Greyling S A, Stevens K, Heyneke P J, Falkson G. Aspergillus brain abscess. A case report. S Afr Med J 1987; 71:116-8.

Hess C F, Brodda K, V Schulthess G K, Thürlimann B, Wurstbauer K. [Importance of thyroid hormone determination in the diagnosis of hyperthyroidism--significant improvement in medical assessment using decision theory results]. Nuklearmedizin 1985; 24:127-34.

Thürlimann B, Falkson G. Gonadotrophin-releasing hormone analogue agonists--a new approach in advanced prostatic cancer. S Afr Med J 1985; 68:888-9.

Thürlimann B. Hormonal treatment of breast cancer: new developments. Oncology 55:501-7.

(c) Swiss Breast Care | Impressum | Datenschutz

Kontaktieren Sie uns

Diese Website verwendet Cookies Mehr Details
OK!